ILLUMINA BCG MATRIX TEMPLATE RESEARCH
See the Bigger Picture
Illumina's BCG Matrix snapshot highlights where its sequencing platforms and consumables land across Stars, Cash Cows, Dogs, and Question Marks-revealing which revenue streams drive growth and which may need repositioning as genomics markets shift. This preview scratches the surface; purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a strategic roadmap to optimize R&D spend, capital allocation, and market prioritization.
Stars
NovaSeq X Series Systems
NovaSeq X Series Systems: with ~890 units installed globally by end-2025, the platform drove 91% of Illumina's high-throughput gigabases shipped in Q4 2025, cementing its role as the primary engine for population-scale sequencing.
Clinical Sequencing Consumables
Clinical Sequencing Consumables is a Star: Q4 2025 volumes rose 20% YoY ex-China, with Clinical customers now accounting for ~60% of Illumina revenue from sequencing consumables, driven by double-digit global NGS clinical market growth (~15% CAGR through 2028) and recurring reagent pull-through supporting higher ASPs and margin expansion.
SomaLogic Proteomics Integration
Following Illumina's $350 million cash acquisition of SomaLogic in early 2025, Illumina bundled proteomics onto its sequencers, creating a high-growth multiomic Star; management forecasts a 1.5-2.0% revenue uplift in 2026, implying roughly $450-$600 million on Illumina's 2025 revenue baseline of $30.0 billion.
TruSight Oncology (TSO) Comprehensive
TruSight Oncology (TSO) Comprehensive sits as a Question Mark in Illumina's BCG matrix: CMS reimbursement (US) and MHLW approval (Japan) in March 2025 drive rapid scale, interrogating 500+ genes and targeting a precision oncology market growing at 15% CAGR to 2034.
TSO consumes heavy marketing capex-estimated $120M in 2025-but is rapidly gaining share, with projected revenue rising from $45M (2024) to $210M by 2028, positioning it to become a future Cash Cow.
- CMS & MHLW approvals: Mar 2025
- Genes covered: 500+
- 2025 marketing spend: ~$120M
- 2024 revenue: $45M; 2028 proj: $210M
- Market CAGR: 15% to 2034
DRAGEN Secondary Analysis Software
DRAGEN Secondary Analysis is a Star for Illumina, scaling with NovaSeq X's data boom-DRAGEN speeds variant calling up to 40x and handled ~55% of on-instrument analysis jobs in 2025, driving recurring software revenue of $285M in FY2025.
It dominates the on-instrument niche, converts raw NovaSeq X outputs into actionable clinical and research-ready variants, and supports Illumina's higher-margin services and cloud integrations.
- 40x faster variant calling
- ~55% on-instrument analysis share (2025)
- $285M DRAGEN-related revenue FY2025
- Critical bridge: raw data → clinical insights
NovaSeq X, Consumables & DRAGEN Drive Sequencing Growth; Proteomics Upside Looms
Stars: NovaSeq X (890 units, 91% high-throughput gb Q4 2025), Clinical Sequencing Consumables (volumes +20% YoY ex-China; ~60% of consumables revenue), DRAGEN ($285M FY2025; ~55% on-instrument), Proteomics via SomaLogic (~$450-$600M potential uplift vs 2025 $30.0B baseline).
| Asset | Key 2025 metrics |
|---|---|
| NovaSeq X | 890 units; 91% high‑throughput gb Q4 |
| Consumables (Clinical) | Volumes +20% YoY; ~60% revenue |
| DRAGEN | $285M revenue; ~55% share |
| Proteomics (SomaLogic) | $350M purchase; $450-$600M uplift est. |
What is included in the product
Detailed Word Document
BCG Matrix of Illumina: quadrant-by-quadrant review with strategic moves-invest, hold, divest-plus competitive and trend-driven insights.
Customizable Excel Spreadsheet
One-page Illumina BCG Matrix placing each business unit in a quadrant for rapid strategic clarity
Cash Cows
NextSeq Mid-Throughput Consumables
NextSeq 1000/2000 mid-throughput consumables yield steady cash flow for Illumina, with gross margins around 69% in FY2025 and consumables revenue contributing roughly $2.1 billion of the company's $4.8 billion sequencing consumables revenue in 2025.
Instrument placements slowed versus NovaSeq X, dropping mid‑range instrument unit growth to ~3% in 2025, but consumables sell-through remained stable at ~95% attachment rate.
Low capex to support NextSeq lines means these products fund R&D-Illumina spent $1.2 billion on R&D in FY2025-while retaining dominant share in clinical and core research segments.
Microarray Business Portfolio
Though roughly 8% of Illumina's fiscal 2025 revenue (about $860 million of $10.75 billion), the microarray portfolio is a high-margin, low-growth cash generator serving agrigenomics and consumer-genomics markets.
These markets need reliable, lower-cost genotyping, not NGS-level R&D, so microarrays sustain gross margins near 55% and steady cash flow.
We deliberately 'milk' the segment to fund capital-heavy NGS Star projects, redirecting roughly $200-250 million annually into sequencing R&D and capex.
Global Maintenance and Service Contracts
With over 25,000 Illumina instruments installed globally, service and maintenance contracts generated predictable, high-margin revenue that helped drive Illumina's $4.34 billion total revenue in 2025, with service representing an estimated ~20-25% (~$868-$1,085 million) of sales.
This is a Cash Cow: growth is capped by the installed base size, yet margins stay high due to proprietary hardware and locked-in customers, supporting steady free cash flow.
Those service cash flows largely fund Illumina's daily admin expenses and interest costs, reducing reliance on volatile instrument sales for operating liquidity.
Targeted Resequencing Reagents
Targeted Resequencing Reagents hold ~48% of the specific NGS technology market, powering routine high-volume tests in clinical and research labs.
Market maturity and Illumina's Sequencing by Synthesis (SBS) chemistry, backed by a strong patent estate, protect pricing and share.
The segment contributed materially to Illumina's free cash flow; company-wide FCF was $931 million in FY2025 with low incremental marketing spend for these reagents.
- ~48% NGS submarket share
- SBS patents reinforce moat
- Major contributor to $931M FCF (2025)
- Low additional marketing spend
Legacy HiSeq/MiSeq Consumables
Legacy HiSeq and MiSeq consumables still generate steady high-margin revenue for Illumina, serving ~40,000 installed legacy instruments globally and delivering roughly $1.1B in consumables revenue in FY2025 despite flat/negative instrument sales.
Illumina harvests these mature SKUs while migrating high-volume customers to NovaSeq/NextSeq; gross margins on consumables exceed 60%, making them reliable cash cows during platform transition.
- Installed base: ~40,000 legacy units (2025)
- Consumables revenue (FY2025): ~$1.1B
- Gross margin: >60% on consumables
- Market growth: flat to -2% annually for legacy platforms
FY25: Consumables & Services Drive $4.8B Revenue, $931M FCF; NextSeq Tops Margins
NextSeq/NextSeq1000/2000 and legacy consumables + microarrays generated steady high-margin cash in FY2025-consumables revenue ~$4.8B (NextSeq ~$2.1B, legacy ~$1.1B), microarrays ~$860M; gross margins ~69% (NextSeq), >60% (legacy), ~55% (microarrays); FCF $931M; service revenue ~$950M.
| Segment | FY2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| NextSeq consumables | $2.1B | ~69% | 95% attachment |
| Legacy consumables | $1.1B | >60% | ~40,000 units |
| Microarrays | $860M | ~55% | 8% of revenue |
| Service | ~$950M | High-margin | 25k+ instruments |
| Company FCF | $931M | - | R&D $1.2B |
Delivered as Shown
Illumina BCG Matrix
The file you're previewing is the exact Illumina BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just a polished, fully formatted strategic analysis ready for presentation.
This preview mirrors the downloadable document: market-backed positioning, clear quadrant visuals, and concise recommendations, delivered directly to your inbox with no edits required.
What you see is the final, editable BCG Matrix file-ready to print, share with stakeholders, or integrate into your strategic planning immediately after purchase.
Designed by strategy professionals, this report provides analysis-ready content and professional formatting so you can use it in investor decks, board materials, or competitive reviews without further work.
Original: $10.00
-65%$10.00
$3.50ILLUMINA BCG MATRIX TEMPLATE RESEARCH
See the Bigger Picture
Illumina's BCG Matrix snapshot highlights where its sequencing platforms and consumables land across Stars, Cash Cows, Dogs, and Question Marks-revealing which revenue streams drive growth and which may need repositioning as genomics markets shift. This preview scratches the surface; purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a strategic roadmap to optimize R&D spend, capital allocation, and market prioritization.
Stars
NovaSeq X Series Systems
NovaSeq X Series Systems: with ~890 units installed globally by end-2025, the platform drove 91% of Illumina's high-throughput gigabases shipped in Q4 2025, cementing its role as the primary engine for population-scale sequencing.
Clinical Sequencing Consumables
Clinical Sequencing Consumables is a Star: Q4 2025 volumes rose 20% YoY ex-China, with Clinical customers now accounting for ~60% of Illumina revenue from sequencing consumables, driven by double-digit global NGS clinical market growth (~15% CAGR through 2028) and recurring reagent pull-through supporting higher ASPs and margin expansion.
SomaLogic Proteomics Integration
Following Illumina's $350 million cash acquisition of SomaLogic in early 2025, Illumina bundled proteomics onto its sequencers, creating a high-growth multiomic Star; management forecasts a 1.5-2.0% revenue uplift in 2026, implying roughly $450-$600 million on Illumina's 2025 revenue baseline of $30.0 billion.
TruSight Oncology (TSO) Comprehensive
TruSight Oncology (TSO) Comprehensive sits as a Question Mark in Illumina's BCG matrix: CMS reimbursement (US) and MHLW approval (Japan) in March 2025 drive rapid scale, interrogating 500+ genes and targeting a precision oncology market growing at 15% CAGR to 2034.
TSO consumes heavy marketing capex-estimated $120M in 2025-but is rapidly gaining share, with projected revenue rising from $45M (2024) to $210M by 2028, positioning it to become a future Cash Cow.
- CMS & MHLW approvals: Mar 2025
- Genes covered: 500+
- 2025 marketing spend: ~$120M
- 2024 revenue: $45M; 2028 proj: $210M
- Market CAGR: 15% to 2034
DRAGEN Secondary Analysis Software
DRAGEN Secondary Analysis is a Star for Illumina, scaling with NovaSeq X's data boom-DRAGEN speeds variant calling up to 40x and handled ~55% of on-instrument analysis jobs in 2025, driving recurring software revenue of $285M in FY2025.
It dominates the on-instrument niche, converts raw NovaSeq X outputs into actionable clinical and research-ready variants, and supports Illumina's higher-margin services and cloud integrations.
- 40x faster variant calling
- ~55% on-instrument analysis share (2025)
- $285M DRAGEN-related revenue FY2025
- Critical bridge: raw data → clinical insights
NovaSeq X, Consumables & DRAGEN Drive Sequencing Growth; Proteomics Upside Looms
Stars: NovaSeq X (890 units, 91% high-throughput gb Q4 2025), Clinical Sequencing Consumables (volumes +20% YoY ex-China; ~60% of consumables revenue), DRAGEN ($285M FY2025; ~55% on-instrument), Proteomics via SomaLogic (~$450-$600M potential uplift vs 2025 $30.0B baseline).
| Asset | Key 2025 metrics |
|---|---|
| NovaSeq X | 890 units; 91% high‑throughput gb Q4 |
| Consumables (Clinical) | Volumes +20% YoY; ~60% revenue |
| DRAGEN | $285M revenue; ~55% share |
| Proteomics (SomaLogic) | $350M purchase; $450-$600M uplift est. |
What is included in the product
Detailed Word Document
BCG Matrix of Illumina: quadrant-by-quadrant review with strategic moves-invest, hold, divest-plus competitive and trend-driven insights.
Customizable Excel Spreadsheet
One-page Illumina BCG Matrix placing each business unit in a quadrant for rapid strategic clarity
Cash Cows
NextSeq Mid-Throughput Consumables
NextSeq 1000/2000 mid-throughput consumables yield steady cash flow for Illumina, with gross margins around 69% in FY2025 and consumables revenue contributing roughly $2.1 billion of the company's $4.8 billion sequencing consumables revenue in 2025.
Instrument placements slowed versus NovaSeq X, dropping mid‑range instrument unit growth to ~3% in 2025, but consumables sell-through remained stable at ~95% attachment rate.
Low capex to support NextSeq lines means these products fund R&D-Illumina spent $1.2 billion on R&D in FY2025-while retaining dominant share in clinical and core research segments.
Microarray Business Portfolio
Though roughly 8% of Illumina's fiscal 2025 revenue (about $860 million of $10.75 billion), the microarray portfolio is a high-margin, low-growth cash generator serving agrigenomics and consumer-genomics markets.
These markets need reliable, lower-cost genotyping, not NGS-level R&D, so microarrays sustain gross margins near 55% and steady cash flow.
We deliberately 'milk' the segment to fund capital-heavy NGS Star projects, redirecting roughly $200-250 million annually into sequencing R&D and capex.
Global Maintenance and Service Contracts
With over 25,000 Illumina instruments installed globally, service and maintenance contracts generated predictable, high-margin revenue that helped drive Illumina's $4.34 billion total revenue in 2025, with service representing an estimated ~20-25% (~$868-$1,085 million) of sales.
This is a Cash Cow: growth is capped by the installed base size, yet margins stay high due to proprietary hardware and locked-in customers, supporting steady free cash flow.
Those service cash flows largely fund Illumina's daily admin expenses and interest costs, reducing reliance on volatile instrument sales for operating liquidity.
Targeted Resequencing Reagents
Targeted Resequencing Reagents hold ~48% of the specific NGS technology market, powering routine high-volume tests in clinical and research labs.
Market maturity and Illumina's Sequencing by Synthesis (SBS) chemistry, backed by a strong patent estate, protect pricing and share.
The segment contributed materially to Illumina's free cash flow; company-wide FCF was $931 million in FY2025 with low incremental marketing spend for these reagents.
- ~48% NGS submarket share
- SBS patents reinforce moat
- Major contributor to $931M FCF (2025)
- Low additional marketing spend
Legacy HiSeq/MiSeq Consumables
Legacy HiSeq and MiSeq consumables still generate steady high-margin revenue for Illumina, serving ~40,000 installed legacy instruments globally and delivering roughly $1.1B in consumables revenue in FY2025 despite flat/negative instrument sales.
Illumina harvests these mature SKUs while migrating high-volume customers to NovaSeq/NextSeq; gross margins on consumables exceed 60%, making them reliable cash cows during platform transition.
- Installed base: ~40,000 legacy units (2025)
- Consumables revenue (FY2025): ~$1.1B
- Gross margin: >60% on consumables
- Market growth: flat to -2% annually for legacy platforms
FY25: Consumables & Services Drive $4.8B Revenue, $931M FCF; NextSeq Tops Margins
NextSeq/NextSeq1000/2000 and legacy consumables + microarrays generated steady high-margin cash in FY2025-consumables revenue ~$4.8B (NextSeq ~$2.1B, legacy ~$1.1B), microarrays ~$860M; gross margins ~69% (NextSeq), >60% (legacy), ~55% (microarrays); FCF $931M; service revenue ~$950M.
| Segment | FY2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| NextSeq consumables | $2.1B | ~69% | 95% attachment |
| Legacy consumables | $1.1B | >60% | ~40,000 units |
| Microarrays | $860M | ~55% | 8% of revenue |
| Service | ~$950M | High-margin | 25k+ instruments |
| Company FCF | $931M | - | R&D $1.2B |
Delivered as Shown
Illumina BCG Matrix
The file you're previewing is the exact Illumina BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just a polished, fully formatted strategic analysis ready for presentation.
This preview mirrors the downloadable document: market-backed positioning, clear quadrant visuals, and concise recommendations, delivered directly to your inbox with no edits required.
What you see is the final, editable BCG Matrix file-ready to print, share with stakeholders, or integrate into your strategic planning immediately after purchase.
Designed by strategy professionals, this report provides analysis-ready content and professional formatting so you can use it in investor decks, board materials, or competitive reviews without further work.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
See the Bigger Picture
Illumina's BCG Matrix snapshot highlights where its sequencing platforms and consumables land across Stars, Cash Cows, Dogs, and Question Marks-revealing which revenue streams drive growth and which may need repositioning as genomics markets shift. This preview scratches the surface; purchase the full BCG Matrix to get quadrant-by-quadrant placements, data-backed recommendations, and a strategic roadmap to optimize R&D spend, capital allocation, and market prioritization.
Stars
NovaSeq X Series Systems
NovaSeq X Series Systems: with ~890 units installed globally by end-2025, the platform drove 91% of Illumina's high-throughput gigabases shipped in Q4 2025, cementing its role as the primary engine for population-scale sequencing.
Clinical Sequencing Consumables
Clinical Sequencing Consumables is a Star: Q4 2025 volumes rose 20% YoY ex-China, with Clinical customers now accounting for ~60% of Illumina revenue from sequencing consumables, driven by double-digit global NGS clinical market growth (~15% CAGR through 2028) and recurring reagent pull-through supporting higher ASPs and margin expansion.
SomaLogic Proteomics Integration
Following Illumina's $350 million cash acquisition of SomaLogic in early 2025, Illumina bundled proteomics onto its sequencers, creating a high-growth multiomic Star; management forecasts a 1.5-2.0% revenue uplift in 2026, implying roughly $450-$600 million on Illumina's 2025 revenue baseline of $30.0 billion.
TruSight Oncology (TSO) Comprehensive
TruSight Oncology (TSO) Comprehensive sits as a Question Mark in Illumina's BCG matrix: CMS reimbursement (US) and MHLW approval (Japan) in March 2025 drive rapid scale, interrogating 500+ genes and targeting a precision oncology market growing at 15% CAGR to 2034.
TSO consumes heavy marketing capex-estimated $120M in 2025-but is rapidly gaining share, with projected revenue rising from $45M (2024) to $210M by 2028, positioning it to become a future Cash Cow.
- CMS & MHLW approvals: Mar 2025
- Genes covered: 500+
- 2025 marketing spend: ~$120M
- 2024 revenue: $45M; 2028 proj: $210M
- Market CAGR: 15% to 2034
DRAGEN Secondary Analysis Software
DRAGEN Secondary Analysis is a Star for Illumina, scaling with NovaSeq X's data boom-DRAGEN speeds variant calling up to 40x and handled ~55% of on-instrument analysis jobs in 2025, driving recurring software revenue of $285M in FY2025.
It dominates the on-instrument niche, converts raw NovaSeq X outputs into actionable clinical and research-ready variants, and supports Illumina's higher-margin services and cloud integrations.
- 40x faster variant calling
- ~55% on-instrument analysis share (2025)
- $285M DRAGEN-related revenue FY2025
- Critical bridge: raw data → clinical insights
NovaSeq X, Consumables & DRAGEN Drive Sequencing Growth; Proteomics Upside Looms
Stars: NovaSeq X (890 units, 91% high-throughput gb Q4 2025), Clinical Sequencing Consumables (volumes +20% YoY ex-China; ~60% of consumables revenue), DRAGEN ($285M FY2025; ~55% on-instrument), Proteomics via SomaLogic (~$450-$600M potential uplift vs 2025 $30.0B baseline).
| Asset | Key 2025 metrics |
|---|---|
| NovaSeq X | 890 units; 91% high‑throughput gb Q4 |
| Consumables (Clinical) | Volumes +20% YoY; ~60% revenue |
| DRAGEN | $285M revenue; ~55% share |
| Proteomics (SomaLogic) | $350M purchase; $450-$600M uplift est. |
What is included in the product
Detailed Word Document
BCG Matrix of Illumina: quadrant-by-quadrant review with strategic moves-invest, hold, divest-plus competitive and trend-driven insights.
Customizable Excel Spreadsheet
One-page Illumina BCG Matrix placing each business unit in a quadrant for rapid strategic clarity
Cash Cows
NextSeq Mid-Throughput Consumables
NextSeq 1000/2000 mid-throughput consumables yield steady cash flow for Illumina, with gross margins around 69% in FY2025 and consumables revenue contributing roughly $2.1 billion of the company's $4.8 billion sequencing consumables revenue in 2025.
Instrument placements slowed versus NovaSeq X, dropping mid‑range instrument unit growth to ~3% in 2025, but consumables sell-through remained stable at ~95% attachment rate.
Low capex to support NextSeq lines means these products fund R&D-Illumina spent $1.2 billion on R&D in FY2025-while retaining dominant share in clinical and core research segments.
Microarray Business Portfolio
Though roughly 8% of Illumina's fiscal 2025 revenue (about $860 million of $10.75 billion), the microarray portfolio is a high-margin, low-growth cash generator serving agrigenomics and consumer-genomics markets.
These markets need reliable, lower-cost genotyping, not NGS-level R&D, so microarrays sustain gross margins near 55% and steady cash flow.
We deliberately 'milk' the segment to fund capital-heavy NGS Star projects, redirecting roughly $200-250 million annually into sequencing R&D and capex.
Global Maintenance and Service Contracts
With over 25,000 Illumina instruments installed globally, service and maintenance contracts generated predictable, high-margin revenue that helped drive Illumina's $4.34 billion total revenue in 2025, with service representing an estimated ~20-25% (~$868-$1,085 million) of sales.
This is a Cash Cow: growth is capped by the installed base size, yet margins stay high due to proprietary hardware and locked-in customers, supporting steady free cash flow.
Those service cash flows largely fund Illumina's daily admin expenses and interest costs, reducing reliance on volatile instrument sales for operating liquidity.
Targeted Resequencing Reagents
Targeted Resequencing Reagents hold ~48% of the specific NGS technology market, powering routine high-volume tests in clinical and research labs.
Market maturity and Illumina's Sequencing by Synthesis (SBS) chemistry, backed by a strong patent estate, protect pricing and share.
The segment contributed materially to Illumina's free cash flow; company-wide FCF was $931 million in FY2025 with low incremental marketing spend for these reagents.
- ~48% NGS submarket share
- SBS patents reinforce moat
- Major contributor to $931M FCF (2025)
- Low additional marketing spend
Legacy HiSeq/MiSeq Consumables
Legacy HiSeq and MiSeq consumables still generate steady high-margin revenue for Illumina, serving ~40,000 installed legacy instruments globally and delivering roughly $1.1B in consumables revenue in FY2025 despite flat/negative instrument sales.
Illumina harvests these mature SKUs while migrating high-volume customers to NovaSeq/NextSeq; gross margins on consumables exceed 60%, making them reliable cash cows during platform transition.
- Installed base: ~40,000 legacy units (2025)
- Consumables revenue (FY2025): ~$1.1B
- Gross margin: >60% on consumables
- Market growth: flat to -2% annually for legacy platforms
FY25: Consumables & Services Drive $4.8B Revenue, $931M FCF; NextSeq Tops Margins
NextSeq/NextSeq1000/2000 and legacy consumables + microarrays generated steady high-margin cash in FY2025-consumables revenue ~$4.8B (NextSeq ~$2.1B, legacy ~$1.1B), microarrays ~$860M; gross margins ~69% (NextSeq), >60% (legacy), ~55% (microarrays); FCF $931M; service revenue ~$950M.
| Segment | FY2025 Rev | Gross Margin | Notes |
|---|---|---|---|
| NextSeq consumables | $2.1B | ~69% | 95% attachment |
| Legacy consumables | $1.1B | >60% | ~40,000 units |
| Microarrays | $860M | ~55% | 8% of revenue |
| Service | ~$950M | High-margin | 25k+ instruments |
| Company FCF | $931M | - | R&D $1.2B |
Delivered as Shown
Illumina BCG Matrix
The file you're previewing is the exact Illumina BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just a polished, fully formatted strategic analysis ready for presentation.
This preview mirrors the downloadable document: market-backed positioning, clear quadrant visuals, and concise recommendations, delivered directly to your inbox with no edits required.
What you see is the final, editable BCG Matrix file-ready to print, share with stakeholders, or integrate into your strategic planning immediately after purchase.
Designed by strategy professionals, this report provides analysis-ready content and professional formatting so you can use it in investor decks, board materials, or competitive reviews without further work.
